Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: A study using tissue microarray

Fetal and Pediatric Pathology

Volumn 32, Issue 3, 2013, Pages 192-204

  Mehrazma, Mitra ^a   Madjd, Zahra ^a   Kalantari, Elham ^a   Panahi, Mahshid ^a   Hendi, Alireza ^a   Shariftabrizi, Ahmad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer stem cells (CSC); CD133; CD44; Pediatric solid tumors

Indexed keywords

CD133 ANTIGEN; HERMES ANTIGEN;

ADOLESCENT; ADVANCED CANCER; ANTIGEN EXPRESSION; CANCER STAGING; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FEMALE; HEPATOBLASTOMA; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PEDIATRIC SOLID TUMOR; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVIEW; RHABDOMYOSARCOMA; SCHOOL CHILD; SOLID TUMOR; TISSUE MICROARRAY; YOLK SAC TUMOR;

ANTIGENS, CD; ANTIGENS, CD44; CHILD; CHILD, PRESCHOOL; FEMALE; GLYCOPROTEINS; HODGKIN DISEASE; HUMANS; INFANT; KIDNEY NEOPLASMS; MALE; NEOPLASM STAGING; NEUROBLASTOMA; PEPTIDES; PROGNOSIS; RETROSPECTIVE STUDIES; STEM CELLS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; WILMS TUMOR;

EID: 84877263343     PISSN: 15513815     EISSN: 15513823     Source Type: Journal    
DOI: 10.3109/15513815.2012.701266     Document Type: Review

References (55)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 414 (6859): 105-11, 2001.
2. Marx J. Cancer research.Mutant stem cellsmay seed cancer. Science 301(5638): 1308-10, 2003.
3. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7): 730-7, 1997.
4. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 98(24): 1755-7, 2006.
5. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26(17): 2839-45, 2008.
6. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100(9): 672-9, 2008.
7. Phillips TM, Mc Bride WH, Pajonk F.The response of CD24(-/low)/CD44 +breast cancer-initiating cells to radiation. J Natl Cancer Inst 98(24): 1777-85, 2006.
8. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65(23): 10946-51, 2005.
9. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65(20): 9328-37, 2005.
10. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 67(3): 1030-7, 2007.
11. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ. Characterization of clonogenicmultiplemyeloma cells. Blood 103(6): 2332-6, 2004.
12. Costa FF, Le Blanc K, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells.. 25(3): 707-11, 2007.
13. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100(7): 3983-8, 2003.
14. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18): 5821-8, 2003.
15. Komuro H, Saihara R, Shinya M, Takita J, Kaneko S, Kaneko M, Hayashi Y. Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines. JPediatr Surg 42(12): 2040-5, 2007.
16. Gatta G, Capocaccia R, Coleman MP, Ries LA, Berrino F. Childhood cancer survival in Europe and the United States. Cancer 95(8): 1767-72, 2002.
17. Friedman GK, Gillespie GY. Cancer Stem Cells and Pediatric Solid Tumors. Cancers (Basel) 3(1): 298-318, 2011.
18. Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 8: 48, 2008.
19. Immervoll H, Hoem D, Steffensen OJ, Miletic H, Molven A. Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for bothmarkers. J Histochem Cytochem 59(4): 441-55, 2011.
20. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, Katz RL.Aldehyde dehydrogenase 1 is a tumor stem cell- associatedmarker in lung cancer.Mol Cancer Res 7(3): 330-8, 2009.
21. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. ALDH1 is a marker of normal andmalignant humanmammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5): 555-67, 2007.
22. Fabian A, Barok M, Vereb G, Szollosi J. Die hard: are cancer stem cells the Bruce Willises of tumor biology? Cytometry A 75(1): 67-74, 2009.
23. Bohl SR, Pircher A, Hilbe W. Cancer stem cells: characteristics and their potential role for new therapeutic strategies. Onkologie 34(5): 269-74, 2011.
24. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol 214(1): 3-9, 2008.
25. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90(12): 5013-21, 1997.
26. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90(12): 5002-12, 1997.
27. Pode-Shakked N, Metsuyanim S, Rom-Gross E, Mor Y, Fridman E, Goldstein I, Amariglio N, Rechavi G, Keshet G, Dekel B.Developmental tumourigenesis: NCAMas a putativemarker for themalignant renal stem/progenitor cell population. J Cell Mol Med 13(8B): 1792-808, 2009.
28. Tong QS, Zheng LD, Tang ST, Ruan QL, Liu Y, Li SW, Jiang GS, Cai JB. Expression and clinical significance of stem cellmarker CD133 in human neuroblastoma.World J Pediatr 4(1): 58-62, 2008.
29. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, Gu J. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120(7): 1444-50, 2007.
30. Tirino V, Desiderio V, d'Aquino R, De Francesco F, Pirozzi G, Graziano A, Galderisi U, Cavaliere C, De Rosa A, Papaccio G, Giordano A. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLo S One 3(10):e3469, 2008.
31. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cellswith cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 104(3): 973-8, 2007.
32. Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, Song YS, Jang KS, Paik SS. Cancer stem cellmarkers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 15(18): 2258-64, 2009.
33. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression.Cancer Res. 15; 53(20): 4754-6, 1993.
34. Woodman AC, Sugiyama M, Yoshida K, Sugino T, Borgya A, Goodison S, Matsumura Y, Tarin D. Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed m RNA and protein isoforms. Am J Pathol 149(5): 1519-30, 1996.
35. Kononen J, Bubendorf L, Kallioniemi A, B̈arlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi O. Tissuemicroarrays for high-throughputmolecular profiling of tumor specimens. Nat Med 4(7): 844-7, 1998.
36. Bubendorf L, Nocito A, Moch H, Sauter G.Tissuemicroarray (TMA)technology:miniaturizedpathology archives for high-throughput in situ studies. J Pathol 195(1): 72-9, 2001.
37. Watson NF, Spendlove I, Madjd Z, McGilvray R, Green AR, Ellis IO, Scholefield JH, Durrant LG. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer 118(6): 1445-52, 2006.
38. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 80(12): 1943-9, 2000.
39. Madjd Z, Mehrjerdi AZ, Sharifi AM, Molanaei S, Shahzadi SZ, Asadi-Lari M. CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Cancer Immun 9: 4, 2009.
40. McCarty KS, Jr., Miller LS, Cox EB, Konrath J, McCarty KS, Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods usingmonoclonal antireceptor antibodies.Arch Pathol Lab Med 109(8): 716-21, 1985.
41. Ehrlich PF, Ritchey ML, Hamilton TE, Haase GM, Ou S, Breslow N, Grundy P, Green D, Norkool P, Becker J, Shamberger RC. Quality assessment for Wilms' tumor: A report from the National Wilms' Tumor Study-5. J Pediatr Surg 40(1): 208-12; discussion 212-3, 2005.
42. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11(8): 1466-77, 1993.
43. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al. SEERCancer Statistics Review, 1975-2005. Available from: http://seer.cancer.gov/csr/1975 2005, 2011.
44. Hill RP. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res 66(4): 1891-5; discussion 1890, 2006.
45. Li MC, Deng YW, Wu J, Chen FH, Liu JF, Fang JS. [Isolation and characterization of brain tumor stem cells in humanmedulloblastoma]. Ai Zheng 25(2): 241-6, 2006.
46. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR Jr, Gillespie GY. CD133 is a marker of bioenergetic stress in human glioma. PLo S One 3(11):e3655, 2008.
47. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM.Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28(45): 3949-59, 2009.
48. Kolenda J, Jensen SS, Aaberg-Jessen C, Christensen K, Andersen C, Br̈unner N, Kristensen BW. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol 103(1): 43-58, 2011.
49. Dekel B, Metsuyanim S, Schmidt-Ott KM, Fridman E, Jacob-Hirsch J, Simon A, Pinthus J, Mor Y, Barasch J, Amariglio N, Reisner Y, Kaminski N, Rechavi G. Multiple imprinted and stemness genes provide a link between normal and tumor progenitor cells of the developing human kidney. Cancer Res 66(12): 6040-9, 2006.
50. Metsuyanim S, Harari-Steinberg O, Buzhor E, Omer D, Pode-Shakked N, Ben-Hur H, Halperin R, Schneider D, Dekel B. Expression of stem cell markers in the human fetal kidney. PLo S One 4(8):e6709, 2009.
51. Friedman GK, Gillespie GY, Pressey JG. Human rhabdomyosarcoma cell lines containmyogenically primitive CD133+ cells that are sensitive to killing by engineered herpes simplex virus, in 2009 ASPHO Abstracts. Pediatr Blood and Cancer. 734, 2009.
52. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS.Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.Mol Cancer 5: 67, 2006.
53. Al Dhaybi R, Sartelet H, Powell J, Kokta V. Expression of CD133+ cancer stem cells in childhood malignantmelanoma and its correlation with metastasis.Mod Pathol 23(3): 376-80, 2010.
54. Balla MM, Vemuganti GK, Kannabiran C, Honavar SG, Murthy R. Phenotypic characterization of retinoblastoma for the presence of putative cancer stem-like cell markers by flow cytometry. Invest Ophthalmol Vis Sci 50(4): 1506-14, 2009.
55. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65(13): 5506-11, 2005.